Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
BörsenkürzelVOR
Name des UnternehmensVor Biopharma Inc
IPO-datumFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
Addresse100 Cambridgepark Drive
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02140
Telefon16176556580
Websitehttps://www.vorbio.com/
BörsenkürzelVOR
IPO-datumFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten